HIK - Hikma Pharmaceuticals PLC
LSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
London,
United Kingdom
Type: Equity
HIK price evolution
HIK
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $236 | $205 | $205 | |
| Short term investments | ||||
| Net receivables | $965 | $965 | $873 | $873 |
| Inventory | $936 | $936 | $891 | $891 |
| Total current assets | $2285 | $2285 | $2100 | $2100 |
| Long term investments | $63 | $63 | $10 | $10 |
| Property, plant & equipment | $1137 | $1137 | $1141 | $1141 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $4847 | $4847 | $4680 | $4680 |
| Current liabilities | ||||
| Accounts payable | $541 | $541 | $568 | $568 |
| Deferred revenue | ||||
| Short long term debt | $215 | $215 | $161 | $161 |
| Total current liabilities | $1380 | $1380 | $1339 | $1339 |
| Long term debt | $1061 | $1061 | $1030 | $1030 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2547 | $2547 | $2471 | $2471 |
| Shareholders' equity | ||||
| Retained earnings | $2287 | $2158 | $2158 | |
| Other shareholder equity | -$309 | -$309 | -$271 | -$271 |
| Total shareholder equity | $2300 | $2300 | $2209 | $2209 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $205 | $270 | $426 | $120 |
| Short term investments | $273 | $227 | ||
| Net receivables | $873 | $841 | $876 | $734 |
| Inventory | $891 | $776 | $695 | $757 |
| Total current assets | $2100 | $1999 | $2094 | $1922 |
| Long term investments | $10 | $52 | $57 | $34 |
| Property, plant & equipment | $1141 | $1081 | $1146 | $1068 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $4680 | $4471 | $4372 | $4135 |
| Current liabilities | ||||
| Accounts payable | $568 | $291 | $262 | $279 |
| Deferred revenue | ||||
| Short long term debt | $161 | $148 | $121 | $168 |
| Total current liabilities | $1339 | $1077 | $1016 | $1028 |
| Long term debt | $1030 | $1135 | $725 | $764 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2471 | $2323 | $1919 | $2000 |
| Shareholders' equity | ||||
| Retained earnings | $2158 | $2092 | $2129 | $2011 |
| Other shareholder equity | -$271 | -$266 | -$224 | -$199 |
| Total shareholder equity | $2209 | $2148 | $2453 | $2135 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $784.5 | $784.5 | $724 | $724 |
| Cost of revenue | $406.5 | $406.5 | $386.5 | $386.5 |
| Gross Profit | $378 | $378 | $337.5 | $337.5 |
| Operating activities | ||||
| Research & development | $30.5 | $30.5 | $42.5 | $42.5 |
| Selling, general & administrative | $140 | $140 | $144.5 | $144.5 |
| Total operating expenses | $583.5 | $566.5 | $566.5 | |
| Operating income | $201 | $201 | $157.5 | $157.5 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $29.5 | $29.5 | $9 | $9 |
| Interest expense | -$22 | -$22 | -$23 | -$23 |
| Net income | ||||
| Net income | $113 | $113 | $29.5 | $29.5 |
| Income (for common shares) | $113 | $113 | $29.5 | $29.5 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2875 | $2517 | $2553 | $2341 |
| Cost of revenue | $1485 | $1252 | $1252 | $1128 |
| Gross Profit | $1390 | $1265 | $1301 | $1213 |
| Operating activities | ||||
| Research & development | $149 | $144 | $143 | $137 |
| Selling, general & administrative | $550 | $509 | $488 | $464 |
| Total operating expenses | $2251 | $1926 | $1955 | $1739 |
| Operating income | $624 | $591 | $598 | $602 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $89 | $42 | $124 | $128 |
| Interest expense | -$90 | -$59 | ||
| Net income | ||||
| Net income | $190 | $188 | $421 | $431 |
| Income (for common shares) | $190 | $188 | $421 | $431 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $113 | $113 | $29.5 | $29.5 |
| Operating activities | ||||
| Depreciation | $26 | $26 | $14.5 | $14.5 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $99 | $193 | $193 | |
| Investing activities | ||||
| Capital expenditures | -$34.5 | -$34.5 | -$42.5 | -$42.5 |
| Investments | ||||
| Total cash flows from investing | -$53 | -$53 | -$107 | -$107 |
| Financing activities | ||||
| Dividends paid | -$52 | -$27.5 | -$27.5 | |
| Sale and purchase of stock | ||||
| Net borrowings | $40.5 | $40.5 | -$63.5 | -$63.5 |
| Total cash flows from financing | -$26 | -$26 | -$119.5 | -$119.5 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $15.5 | $15.5 | -$33.5 | -$33.5 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $190 | $188 | $544 | $558 |
| Operating activities | ||||
| Depreciation | $102 | $182 | $145 | $91 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $608 | $530 | $638 | $464 |
| Investing activities | ||||
| Capital expenditures | -$169 | -$138 | -$229 | -$224 |
| Investments | ||||
| Total cash flows from investing | -$333 | -$607 | -$238 | -$283 |
| Financing activities | ||||
| Dividends paid | -$137 | -$125 | -$120 | -$109 |
| Sale and purchase of stock | -$300 | -$375 | ||
| Net borrowings | -$103 | $447 | -$114 | $220 |
| Total cash flows from financing | -$337 | -$58 | -$287 | -$298 |
| Effect of exchange rate | -$7 | -$10 | -$2 | |
| Change in cash and equivalents | -$65 | -$156 | $103 | -$119 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $3.02B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $285.00M |
| Revenue Q/Q | 9.95% |
| Revenue Y/Y | 10.47% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | 5.98% |
| ROE | 12.64% |
| Debt/Equity | 1.12 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.66 |
| Quick ratio | 0.98 |